Brompheniramine
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Brompheniramine: From Allergic Rhinitis to Allergic Urticaria
One-Sentence Summary
Brompheniramine is a first-generation H1 receptor antagonist classically used for symptomatic relief of allergic rhinitis and common cold symptoms. The TxGNN model predicts it may be effective for Allergic Urticaria, with 0 clinical trials and 0 publications currently indexed in the query dataset — though this likely reflects data collection scope rather than a true evidence gap, as H1 antihistamines are first-line therapy for urticaria per international dermatology guidelines.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, common cold symptoms (first-generation H1 antihistamine class) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L5 |
| US Market Status | Not Marketed (no NDA on record) |
| Number of NDAs | 0 |
| Recommended Decision | Hold (Research Question) |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the structured data inputs. Based on the drug class and repurposing rationale, brompheniramine is a first-generation H1 receptor antagonist — it works by competitively and reversibly blocking histamine H1 receptors, thereby preventing histamine-mediated vasodilation, increased vascular permeability, smooth muscle contraction, and pruritus.
Allergic urticaria (hives) is mechanistically driven by IgE-mediated mast cell degranulation, which releases large quantities of histamine that act on cutaneous microvascular H1 receptors — producing wheals (wind-rush plaques), flare, and itch. Brompheniramine directly blocks this pathway. The TxGNN score of 0.9987 (near perfect) is fully consistent with this mechanistic alignment; the model is essentially recognising a canonical drug-class effect rather than a novel repurposing leap.
It is important to note that zero clinical trial and literature hits in the query dataset almost certainly reflects data collection scope limitations rather than a genuine clinical evidence vacuum. H1 antihistamines — including first-generation agents such as brompheniramine, chlorpheniramine, and hydroxyzine — are the cornerstone first-line treatment for allergic urticaria in EAACI, AAD, and AAAAI guidelines. The prediction should therefore be interpreted as a confirmation of established pharmacology rather than a speculative repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered in the queried dataset for brompheniramine + allergic urticaria.
Note: Absence of indexed trials reflects query scope. Broader searches using class-level terms (e.g., “first-generation antihistamine,” “chlorpheniramine,” “urticaria”) would likely surface substantial Phase 3 evidence for the H1 antihistamine class as a whole.
Literature Evidence
Currently no related literature available in the queried dataset for brompheniramine + allergic urticaria.
Note: Same caveat as above — class-level PubMed queries for H1 antihistamines in urticaria management yield thousands of publications, including multiple systematic reviews and RCTs.
US Market Information
No NDA records found for brompheniramine in the queried regulatory database.
Note: Brompheniramine is widely available in the United States as an OTC ingredient in multi-symptom cold and allergy combination products (e.g., Dimetapp). It may be registered under OTC monograph frameworks rather than individual NDAs, which would explain the absence of records in an NDA-centric query.
Safety Considerations
Please refer to the package insert for safety information.
All structured safety fields (key warnings, contraindications, drug–drug interactions) returned no data in this query cycle. As a first-generation antihistamine, known class-level concerns include sedation / CNS depression, anticholinergic effects (dry mouth, urinary retention, blurred vision), and potential QTc prolongation at high doses — prescribers should consult the current labelling before use.
Conclusion and Next Steps
Decision: Hold (Research Question)
Rationale: The TxGNN prediction is mechanistically sound and reflects established pharmacology; however, the current evidence pack contains no structured clinical trials, literature, or regulatory approval data for brompheniramine + allergic urticaria, yielding an L5 evidence level that is insufficient to support a formal repurposing recommendation without further documentation.
To proceed, the following is needed:
- Expand literature search: Run class-level PubMed queries (H1 antihistamines + urticaria) to confirm the expected body of clinical evidence and determine whether brompheniramine specifically has been studied versus class analogues only
- Regulatory clarification: Determine whether brompheniramine is covered under the US OTC antihistamine monograph (21 CFR Part 341) rather than individual NDAs, and document the relevant OTC approval pathway
- MOA data: Obtain full DrugBank MOA, pharmacodynamics, and toxicity profile to complete the mechanism-of-action analysis (DG002 remediation)
- Safety data: Download and parse the TFDA/FDA package insert to populate key warnings, contraindications, and drug interaction data (DG001 remediation)
- Decision upgrade pathway: If class-level evidence is confirmed (highly likely), this candidate could be upgraded to Proceed with Guardrails — the primary remaining gap is brompheniramine-specific trial data rather than a fundamental mechanistic question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.